A phase 1 study evaluating ABT-414 in combination with
temozolomide (TMZ) for subjects with recurrent or unresectable
glioblastoma (GBM).
2014 ASCO Annual Meeting
• Antibody targeting EGFR or mutant EGFRvIII conjugated to a cytotoxic anti-
microtubule agent
• Preclinical activity against GBM tumor models - either amplified wild type
EGFR or EGFRvIII
• Preliminary safety data demonstrate unique toxicity - corneal epithelial
microcysts
• Preliminary responses in 3/9 pts with TMZ refractory GBM; 1 CR
• Phase 2 studies of ABT-414 in GBM underway:
–
With TMZ in recurrent GBM (EGFR amplified or EGFRvIII mutated)
–
With RT-TMZ in first line GBM (EGFR amplified or EGFRvIII mutated)